SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

“Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people ...

PMN 310 has successfully completed a Phase 1a clinical study and is dosing Alzheimer's disease patients in a Phase 1b clinical trial in AD patients. ProMIS has offices in Cambridge, Massachusetts and ...

PMN 310 has successfully completed a Phase 1a clinical study and is dosing Alzheimer’s disease patients in a Phase 1b clinical trial in AD patients. ProMIS has offices in Cambridge ...

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating ... Assembly Biosciences, Inc. - (GLOBE NEWSWIRE) Feb 20, 2025 ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström MacroglobulinemiaFirst-in-class ...

NXP800 Phase 1b study in patients with platinum resistant ... Mr. Bentsur continued, "For NXP900, enrollment continues in the Phase 1a dose escalation clinical trial and we are pleased with the ...

is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase 1b results for the treatment of psoriasis. SFA Therapeutics has also received clearance of its Investigational New ...

Tenaya Therapeutics, Inc. announced the initiation of dosing in Cohort 2 of its MyPEAK™-1 Phase 1b/2 clinical trial for TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM).

Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company with a market capitalization of $78.44 million, has announced the initiation of a Phase 1a clinical trial for ABI-6250 ...